RE-BVS – Piemonte Repository

Sfoglia per AUTORE
ALBANO F
Collezione AOU Alessandria

Items : 4

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino

Fazi P; Vignetti M; Guarini A; Cuneo A; Piciocchi A; De Propris MS; Nanni M; Del Giudice I; Neri A; De Novi LA; Albano F; Vitale C; Visentin A; Pietrasanta D; Mattiello V; Molinari MC; Liberati AM; Giordano A; Patrizi VB; Gottardi D; Galieni P; Deodato M; Arcari A; Musuraca G; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. in Blood / Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.

2021
AOU Alessandria

Rigolin GM; Del Giudice I; Bardi A; Melandri A; García-Jacobo RE; Cura F; Raponi S; Ilari C; Cafforio L; Piciocchi A; Arena V; Reda G; Albano F; Molica S; Sportoletti P; Trentin L; Marchetti M; Nanni M; Peragine N; Mariglia P; Vignetti M; Guarini A; Mauro FR; Foà R; Cuneo A;

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). in Haematologica / Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.

2020
AOU Alessandria
AOU Città della Salute di Torino

Della Starza I; Del Giudice I; Cuneo A; Albano F; Neri A; Vignetti M; Piciocchi A; Nanni M; Musolino C; Del Poeta G; Battistini R; Gozzetti A; Pietrasanta D; Reda G; Tedeschi A; Liberati AM; Re F; Angelucci E; Zaja F; Coscia M; Ilariucci F; Soddu S; Molica S; Mauro FR; De Propris MS; Raponi S; Guarini AR; Foà R;

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. in Blood advances / Blood Adv. 2019 Dec 23;3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.

2019
AOU Alessandria
AOU Città della Salute di Torino

Rupoli S; Rege-Cambrin G; Rapezzi D; Pregno P; Palmieri F; Musolino C; Montefusco E; Melpignano A; Miggiano MC; Martino B; Marasca R; Malagola M; Lunghi M; Lunghi F; Luciano L; Lucchesi A; Levato L; La Barba G; Iurlo A; Gozzini A; Gugliotta G; Giai V; Galimberti S; Fozza C; Fazi P; Fava C; Elena C; D'Adda M; Crugnola M; et alii...